Evidence map›Paper›PMID 37907459›Full record

ArticleNature communications2023

Defining neutralization and allostery by antibodies against COVID-19 variants.

Nikhil Kumar Tulsian, Raghuvamsi Venkata Palur, Xinlei Qian, Yue Gu, Bhuvaneshwari D/O Shunmuganathan, Firdaus Samsudin, Yee Hwa Wong, Jianqing Lin, Kiren Purushotorman, Mary McQueen Kozma and 6 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Nikhil Kumar Tulsian *Department of Biological Sciences, National University of Singapore, Singapore, 117543, Singapore. nikhilkt.science@gmail.com.ORCID 0000-0001-6577-6748
Raghuvamsi Venkata Palur *Department of Biological Sciences, National University of Singapore, Singapore, 117543, Singapore.
Xinlei Qian *Antibody Engineering Programme, Life Sciences Institute, National University of Singapore, Singapore, 117546, Singapore.
Yue GuAntibody Engineering Programme, Life Sciences Institute, National University of Singapore, Singapore, 117546, Singapore.
Bhuvaneshwari D/O ShunmuganathanAntibody Engineering Programme, Life Sciences Institute, National University of Singapore, Singapore, 117546, Singapore.
Firdaus SamsudinBioinformatics Institute, Agency for Science, Technology, and Research (A*STAR), Singapore, 138761, Singapore.
Yee Hwa WongSchool of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore.ORCID 0000-0002-2751-9721
Jianqing LinSchool of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore.ORCID 0000-0003-4336-9003
Kiren PurushotormanAntibody Engineering Programme, Life Sciences Institute, National University of Singapore, Singapore, 117546, Singapore.ORCID 0000-0002-6640-1144
Mary McQueen KozmaAntibody Engineering Programme, Life Sciences Institute, National University of Singapore, Singapore, 117546, Singapore.
Bei WangSingapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.ORCID 0000-0002-3112-7341
Julien LescarSchool of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore.ORCID 0000-0002-9623-8130
Cheng-I WangSingapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, 138648, Singapore.ORCID 0000-0001-9170-2996
Ravindra Kumar GuptaDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117546, Singapore.
Peter John BondDepartment of Biological Sciences, National University of Singapore, Singapore, 117543, Singapore. peterjb@bii.a-star.edu.sg.ORCID 0000-0003-2900-098X
Paul Anthony MacAryDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117546, Singapore. micpam@nus.edu.sg.ORCID 0000-0002-1139-8996
National University of Singapore · SGAgency for Science, Technology and Research · SGNanyang Technological University · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The changing landscape of SARS-CoV-2 Spike protein is linked to the emergence of variants, immune-escape and reduced efficacy of the existing repertoire of anti-viral antibodies. The functional activity of neutralizing antibodies is linked to their quaternary changes occurring as a result of antibody-Spike trimer interactions. Here, we reveal the conformational dynamics and allosteric perturbations linked to binding of novel human antibodies and the viral Spike protein. We identified epitope hotspots, and associated changes in Spike dynamics that distinguish weak, moderate and strong neutralizing antibodies. We show the impact of mutations in Wuhan-Hu-1, Delta, and Omicron variants on differences in the antibody-induced conformational changes in Spike and illustrate how these render certain antibodies ineffective. Antibodies with similar binding affinities may induce destabilizing or stabilizing allosteric effects on Spike, with implications for neutralization efficacy. Our results provide mechanistic insights into the functional modes and synergistic behavior of human antibodies against COVID-19 and may assist in designing effective antiviral strategies.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralHumansNeutralization TestsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID37907459
PMCPMC10618280
OpenAlexW4388134894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.